Showing 1891-1900 of 7317 results for "".
Off-label Uses for Biologics
https://practicaldermatology.com/topics/psoriasis/off-label-uses-for-biologics/18964/Derm Insider Bonus Content: Host Neal Bhatia speaks with guests Alice Gottlieb, MD, Harold Farber, MD, and James Ulery, MD about various potential off-label uses for current and investigational systemic psoriasis therapies.Neotensil®: A Novel, Noninvasive Solution That Reduces the Appearance of Under-Eye Bags
https://practicaldermatology.com/topics/practice-management/neotensil-a-novel-noninvasive-solution-that-reduces-the-appearance-of-under-eye-bags/19058/Neotensil is the only noninvasive solution clinically proven to reduce the appearance of under-eye bags within an hour, with benefits that last up to 16 hours. Doris Day, MD, discusses the benefits of Neotensil, as well as patient selection, staff training and how to incorporate this unique and effeThe Importance of Planning
https://practicaldermatology.com/topics/practice-management/the-importance-of-planning/19082/Failing to plan is planning to fail, say Jay A. Shorr, BA, MBM-C, CAC I-V and Mara Shorr, BS, CAC II-V of The Best Medical Business Solutions. They tell aesthetic practices how to lay the foundation for success in minimally invasive procedures.Using GEP Test Results to Manage Patients
https://reachmd.com/programs/practical-dermatology-updates-in-skin-cancer/using-gep-test-results-to-manage-patients/35603/Jason M. Rizzo, MD, describes how gene expression profile (GEP) testing works and how the results can be used to manage patients from a dermatologist's perspective.The Importance and Utility of GEP Testing
https://practicaldermatology.com/series/updates-in-skin-cancer/the-importance-and-utility-of-gep-testing/35597/Hadas Skupsky, MD, a board-certified dermatologist and dermatopathologist, discusses gene expression profiling technology and its importance in the diagnosis and prognostication of melanomas.Skin Coverage as a Medical Benefit
https://practicaldermatology.com/series/c-suite-chats/skin-coverage-as-a-medical-benefit/35559/Mike Jafar, Founder and CEO of Joya Health, talks about the importance of having skin coverage as a medical benefit, trends in dermatology, and the driver behind the rising rates of melanoma.Journal Club: S. Aureus-Driven AD Exacerbation
https://reachmd.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-s-aureus-driven-ad-exacerbation/32404/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses a recent Journal of Drugs in Dermatology article about the need for a novel treatment for S. aureus exacerbated atopic dermatitis with Adelaide Hebert, MD.Schachner LA, Andriessen A, Gonzalez ME, Lal K, Hebert AA, EAddressing Equity Gaps in Psoriasis Research
https://practicaldermatology.com/series/c-suite-chats/addressing-equity-gaps-in-psoriasis-research/33151/LaShell Robinson, Head, Global Feasibility and Trial Equity for Takeda, discusses the disproportionate underrepresentation of certain racial and ethnic groups in clinical trials, especially for psoriasis, and how Takeda is seeking to close those gaps in recent Phase 3 trials.Dr. Tsao, Dr. Friedlander Recap Biggest Developments for Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-tsao-dr-friedlander-recap-biggest-developments-for-maui-derm/32913/The development of new therapeutics for dermatologic conditions in recent years has been so prolific that Hensin Tsao, MD, PhD, used a “Maui Journal of Medicine” theme for his conference-opening presentation at the Maui Derm Hawaii 2025 meeting in Maui, Hawaii.- Risk Stratification Testing for Melanomahttps://practicaldermatology.com/series/c-suite-chats/risk-stratification-testing-for-melanoma/32838/Derek Maetzold, president and CEO of Castle Biosciences, discusses the importance of personalized management and treatment approaches for patients diagnosed with melanoma, and how gene expression profile testing can help.